Back to results
US 2021/0239703 A1Published application
Pd1 and pdl-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsAlan List, Sheng Wei
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method for diagnosing in a subject the progression from myelodysplastic syndrome (MDS) to acute myelogenous leukemia (AML). Also disclosed are methods of treating AML in a subject diagnosed by the disclosed methods.
Claims13
A method for treating acute myelogenous leukemia (AML) in a subject, comprising:
- assaying a sample from the subject for the expression of PD-1 on CD71+ and CD34+ progenitor cells, the expression of PD-L1 on CD33+ myeloid derived stem cells (MDSCs), or a combination thereof,
- detecting an increase in PD-1 expression on progenitor cells or decrease in PD-L1 expression on MDSCs as an indication of progression from myelodysplastic syndrome (MDS) to AML, and
- treating the subject for AML.
(canceled)
13-24. (canceled)
Dependencies are inferred from the claim text.